AstraZeneca PLC – NASDAQ:AZN
AstraZeneca stock price today
$79.54
+13.28
+20.04%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
AstraZeneca stock price monthly change
-16.38%
month
AstraZeneca stock price quarterly change
-16.38%
quarter
AstraZeneca stock price yearly change
-1.62%
year
AstraZeneca key metrics
Market Cap | 203.71B |
Enterprise value | 232.21B |
P/E | 31.62 |
EV/Sales | 4.53 |
EV/EBITDA | 15.51 |
Price/Sales | 4.01 |
Price/Book | 5.04 |
PEG ratio | -51.54 |
EPS | 2.05 |
Revenue | 47.61B |
EBITDA | 13.25B |
Income | 6.33B |
Revenue Q/Q | 16.54% |
Revenue Y/Y | 8.60% |
Profit margin | 12.68% |
Oper. margin | 17.97% |
Gross margin | 80.88% |
EBIT margin | 17.97% |
EBITDA margin | 27.84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAstraZeneca stock price history
AstraZeneca stock forecast
AstraZeneca financial statements
Average Price Target
$88.5
Potential upside: 11.26%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 11.41B | 1.81B | 15.93% |
|---|---|---|---|
| Sep 2023 | 11.49B | 1.37B | 11.96% |
| Dec 2023 | 12.02B | 960M | 7.98% |
| Mar 2024 | 12.67B | 2.17B | 17.19% |
2.22%
Yield TTM
| Payout ratio | 71.25% |
|---|
| 2019 | 2.77% |
|---|---|
| 2020 | 2.72% |
| 2021 | 2.33% |
| 2022 | 2.08% |
| 2023 | 2.15% |
| Jun 2023 | 96543000000 | 59.12B | 61.24% |
|---|---|---|---|
| Sep 2023 | 96086000000 | 58.86B | 61.26% |
| Dec 2023 | 101119000000 | 61.95B | 61.27% |
| Mar 2024 | 102293000000 | 64.79B | 63.34% |
| Jun 2023 | 1.71B | -520M | -1.51B |
|---|---|---|---|
| Sep 2023 | 3.11B | -1.22B | -2.72B |
| Dec 2023 | 2.38B | -1.07B | -291M |
| Mar 2024 | 2.57B | -2.50B | 2.02B |
AstraZeneca alternative data
AstraZeneca Social Media Accounts
What are followers?
+1.06%
month
| May 2025 | 82622 |
|---|---|
| Jul 2025 | 84604 |
| Aug 2025 | 85498 |
+21.43%
month
+68.97%
quarter
| Sep 2023 | 84 |
|---|---|
| Oct 2023 | 95 |
| Nov 2023 | 112 |
| Dec 2023 | 136 |
What is job openings count?
| Sep 2023 | 1,976 |
|---|---|
| Oct 2023 | 1,969 |
| Nov 2023 | 1,945 |
| Dec 2023 | 1,666 |
| Jan 2024 | 1,309 |
| Feb 2024 | 1,752 |
| Apr 2024 | 1,700 |
| May 2024 | 1,718 |
| Jan 2025 | 880 |
| Feb 2025 | 1,216 |
| May 2025 | 1,189 |
| Jul 2025 | 1,215 |
| Sep 2023 | 83,500 |
|---|---|
| Oct 2023 | 83,500 |
| Nov 2023 | 83,500 |
| Dec 2023 | 83,500 |
| Jan 2024 | 83,500 |
| Feb 2024 | 83,500 |
| Mar 2024 | 83,500 |
| Apr 2024 | 83,500 |
| May 2024 | 83,500 |
| Jun 2024 | 89,900 |
| Jul 2024 | 89,900 |
AstraZeneca other data
15.63%
-19.73%
of AZN is owned by hedge funds
792
-148
223.10M
-281.57M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 8 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 28 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Pascal Soriot D.V.M., M.B.A. (1959) Chief Executive Officer & Executive Director | $5,960,000 |
| Mr. Marc Dunoyer (1952) Chief Executive Officer of Alexion | $3,330,000 |
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients
3 Of The Best SWANs On My Shopping List
Merck Stock Is Almost A Classical Benjamin Graham Investment
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
Pfizer: Building The Next Oncology Empire
Why Novartis Is Still A 'Buy' After 15% Surge
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
-
What's the price of AstraZeneca stock today?
One share of AstraZeneca stock can currently be purchased for approximately $79.54.
-
When is AstraZeneca's next earnings date?
Unfortunately, AstraZeneca's (AZN) next earnings date is currently unknown.
-
Does AstraZeneca pay dividends?
Yes, AstraZeneca pays dividends and its trailing 12-month yield is 2.23% with 71% payout ratio. The last AstraZeneca stock dividend of $0.44 was paid on 13 Sep 2021.
-
How much money does AstraZeneca make?
AstraZeneca has a market capitalization of 203.71B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.29% to 45.81B US dollars.
-
What is AstraZeneca's stock symbol?
AstraZeneca PLC is traded on the NASDAQ under the ticker symbol "AZN".
-
What is AstraZeneca's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of AstraZeneca?
Shares of AstraZeneca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AstraZeneca's key executives?
AstraZeneca's management team includes the following people:
- Mr. Pascal Soriot D.V.M., M.B.A. Chief Executive Officer & Executive Director(age: 66, pay: $5,960,000)
- Mr. Marc Dunoyer Chief Executive Officer of Alexion(age: 73, pay: $3,330,000)
-
How many employees does AstraZeneca have?
As Jul 2024, AstraZeneca employs 89,900 workers, which is 8% more then previous quarter.
-
When AstraZeneca went public?
AstraZeneca PLC is publicly traded company for more then 32 years since IPO on 12 May 1993.
-
What is AstraZeneca's official website?
The official website for AstraZeneca is astrazeneca.com.
-
How can i contact AstraZeneca?
AstraZeneca can be reached via phone at +44 20 3749 5000.
-
What is AstraZeneca stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for AstraZeneca in the last 12 months, the avarage price target is $88.5. The average price target represents a 11.26% change from the last price of $79.54.
AstraZeneca company profile:
AstraZeneca PLC
astrazeneca.comExchange:
NASDAQ
Full time employees:
89,900
Industry:
Drug Manufacturers - General
Sector:
Healthcare
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
1 Francis Crick Avenue
Cambridge, CB2 0AA
Cambridge, CB2 0AA
CIK: 0000901832
ISIN: US0463531089
CUSIP: 046353108
